Nociception

No Sensors Needed: Fern Study Shows User Feedback Can Appropriately Modulate Digital Pain Programs

Retrieved on: 
Wednesday, June 30, 2021

The eight-week study examined the efficacy of self-reported participant musculoskeletal (MSK) pain intensity and perceived exertion scores in modulating digitally-delivered exercise therapy.

Key Points: 
  • The eight-week study examined the efficacy of self-reported participant musculoskeletal (MSK) pain intensity and perceived exertion scores in modulating digitally-delivered exercise therapy.
  • Conducted in early 2021, the study focused on 89 participants aged 18-75 who had back, neck, shoulder, knee, or hip pain.
  • Pain intensity was scored using the Numeric Pain Rating Scale (NPRS), a unidimensional measure of pain intensity in adults, including those with chronic pain.
  • Available through employers, Fern Health 's virtual pain platform addresses the underlying cause of persistent pain, not just the symptoms.

Clearway Pain Solutions Merges with The Center for Pain

Retrieved on: 
Wednesday, June 30, 2021

ANNAPOLIS, Md., June 30, 2021 /PRNewswire/ -- Clearway Pain Solutions has merged with The Center for Pain creating one of the largest integrated pain solutions practices in the U.S. with 40 doctors and 59 clinical practitioners serving 43 locations in Maryland, Florida, Alabama, and Delaware.

Key Points: 
  • ANNAPOLIS, Md., June 30, 2021 /PRNewswire/ -- Clearway Pain Solutions has merged with The Center for Pain creating one of the largest integrated pain solutions practices in the U.S. with 40 doctors and 59 clinical practitioners serving 43 locations in Maryland, Florida, Alabama, and Delaware.
  • "This is a celebration of two extraordinary teams joining together to bring clinical excellence to the communities of Alabama," says Clearway Pain Solutions CEO, Dr. Damean Freas.
  • Clearway Pain Solutions is the flagship brand with the corporate headquarters in Annapolis, MD.
  • Dr. Freas also explained that the broader Clearway Pain Solutions platform is good for those needing a trusted practice to send patients in need of specialized pain management.

Neuros Medical Receives FDA Breakthrough Device Designation for its Novel Altius® High Frequency Nerve Block System

Retrieved on: 
Tuesday, June 29, 2021

Chronic post-amputation pain is a significant unmet medical need, as existing treatment options are limited, and consist primarily of opioids and gabapentinoids.

Key Points: 
  • Chronic post-amputation pain is a significant unmet medical need, as existing treatment options are limited, and consist primarily of opioids and gabapentinoids.
  • Neuros anticipates completion of enrollment in its pivotal QUEST (High-FreQUEncy Nerve Block for PoST-Amputation Pain) study by the Fall of 2021.
  • QUEST is designed to assess the safety & effectiveness of the Company's AltiusHigh-Frequency Nerve Block system to treat intractable chronic post-amputation pain.
  • Neuros Medical, a neuromodulation company, has developed the Altius system for the treatment of chronic post-amputation pain (Phantom Limb Pain and Residual Limb Pain).

New Study – WEA Trust Reduces Spend by 56% and Opioid Use by 87% with Kiio Digital Musculoskeletal Care

Retrieved on: 
Thursday, June 24, 2021

Overall, Kiio participants had a 56% lower combined medical and pharmacy spend as compared to the traditional care group.

Key Points: 
  • Overall, Kiio participants had a 56% lower combined medical and pharmacy spend as compared to the traditional care group.
  • Kiio members had 47% lower antidepressant use than WEA Trust members with a low back pain diagnosis who did not participate in Kiio.
  • Bartholow continued, WEA Trust believes in taking a leadership role to high-value, innovative care delivery models like Kiio that provide members with immediate access, convenience, and supported control over their health outcomes.
  • Claims-based studies show that Kiio significantly reduces pain, opioid use, and medical spend while improving function, productivity, and quality of life.

Global Pain Management Drugs Market (2021 to 2026) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 23, 2021

The "Pain Management Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pain Management Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global pain management drugs market reached a value of US$ 74 Billion in 2020.
  • Looking forward, the publisher expects the global pain management drugs market to exhibit moderate growth during the forecast period (2021-2026).
  • Pain management drugs perform pharmacological actions on pain receptors and work against discomfort-causing symptoms.

Implantable Brain Device Relieves Pain in Early Study

Retrieved on: 
Monday, June 21, 2021

NEW YORK, June 21, 2021 /PRNewswire/ -- A computerized brain implant effectively relieves short-term and chronic pain in rodents, a new study finds.

Key Points: 
  • NEW YORK, June 21, 2021 /PRNewswire/ -- A computerized brain implant effectively relieves short-term and chronic pain in rodents, a new study finds.
  • According to the study authors, this suggests that the device reduced the intensity of the pain the rodents experienced.
  • Researchers say the investigation is the first to use a computerized brain implant to detect and relieve bursts of pain in real time.
  • A computer linked to the device then automatically identifies electrical patterns in the brain closely linked to pain.

NeuraLace Announces FDA 510(k) Clearance and U.S. Launch of Axon Therapy® Peripheral Nerve Stimulation System For Chronic Pain Relief

Retrieved on: 
Thursday, June 17, 2021

SAN DIEGO, June 17, 2021 /PRNewswire/ --NeuraLace Medical, Inc., a medical device company focused on improving pain relief among patients suffering from debilitating chronic pain, announced today that it has received FDA 510(k) clearance for Axon Therapy to non-invasively stimulate peripheral nerves and provide chronic nerve pain relief.

Key Points: 
  • SAN DIEGO, June 17, 2021 /PRNewswire/ --NeuraLace Medical, Inc., a medical device company focused on improving pain relief among patients suffering from debilitating chronic pain, announced today that it has received FDA 510(k) clearance for Axon Therapy to non-invasively stimulate peripheral nerves and provide chronic nerve pain relief.
  • "We believe Axon Therapy is a significant step forward on the care continuum that is accessible to patients today and we look forward to bringing sustainable pain relief to patients by launching Axon Therapy in the United States."
  • Axon Therapy delivers focused magnetic pulses which activate the damaged peripheral nerve axons that are required to provide relief from chronic nerve pain.
  • Our mission to end chronic pain inspired us to develop Axon Therapy, with the goal of being the first non-invasive, non-addictive way to effectively treat chronic nerve pain.

Collegium Announces Publication of Real-World Data in Journal of Pain Research

Retrieved on: 
Wednesday, June 16, 2021

We will continue to support the analysis and publication of real-world data as it becomes available.

Key Points: 
  • We will continue to support the analysis and publication of real-world data as it becomes available.
  • The publication can be found here: link
    Collegium is a specialty pharmaceutical company committed to being the leader in responsible pain management.
  • Xtampza ER (oxycodone) is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
  • Assess each patients risk prior to prescribing Xtampza ER and monitor all patients regularly for the development of these behaviors or conditions.

NeuroMetrix Reports that Quell® Technology is to be Evaluated for Neuromyelitis Optica Spectrum Disorder (NMOSD) in a Randomized Controlled Trial

Retrieved on: 
Tuesday, June 15, 2021

It has been shown to be effective in some forms of neuropathic pain, but has not been extensively evaluated for NMOSD.

Key Points: 
  • It has been shown to be effective in some forms of neuropathic pain, but has not been extensively evaluated for NMOSD.
  • The trial will use a modified Quell device and mobile app that allow for an alternative electrode placement and stimulation pattern.
  • "This rigorous randomized controlled trial will add to the growing body of clinical data on the utility of Quell technology in chronic pain conditions with a neuropathic pain component.
  • Quell is a wearable neurostimulation device indicated for symptomatic relief of lower extremity chronic pain that is available over-the-counter.

OliPass Expands Scientific Advisory Board by Inviting Experts in Pain To Bolster Phase 2 Clinical Trial Design and Management

Retrieved on: 
Thursday, June 10, 2021

Professor Dougherty and Professor Dworkin will advise OliPass on Phase 2 clinical trials of OLP-1002.

Key Points: 
  • Professor Dougherty and Professor Dworkin will advise OliPass on Phase 2 clinical trials of OLP-1002.
  • Considering the pharmacological complexity of neuropathic pain, however, expertise in neuropathic pain and in clinical study design will be critical to a success in the clinical development of OLP-1002 against neuropathic pain.
  • We are very much honored to have Professor Dougherty and Professor Dworkin as new SAB members as we develop the first-in-class pain killer.
  • He has significantly contributed to defining mechanism of cancer therapy-induced pain and identifying potential therapeutic interventions for its relief or prevention.